589 related articles for article (PubMed ID: 16360549)
1. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004).
Goossens H; Grabein B
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):257-64. PubMed ID: 16360549
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
[TBL] [Abstract][Full Text] [Related]
3. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).
Hirakata Y; Matsuda J; Miyazaki Y; Kamihira S; Kawakami S; Miyazawa Y; Ono Y; Nakazaki N; Hirata Y; Inoue M; Turnidge JD; Bell JM; Jones RN; Kohno S;
Diagn Microbiol Infect Dis; 2005 Aug; 52(4):323-9. PubMed ID: 16165001
[TBL] [Abstract][Full Text] [Related]
4. [Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infection in Spain: SMART 2003 study outcomes].
Baquero F; Cercenado E; Cisterna R; de la Rosa M; García-Rodríguez JA; Gobernado M; Pérez JL; Manchado P; Martín R; Pascual A; Picazo J; Prats G; Rubio C; Snyder TA; Sanz-Rodríguez C
Rev Esp Quimioter; 2006 Mar; 19(1):51-9. PubMed ID: 16688292
[TBL] [Abstract][Full Text] [Related]
5. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
[TBL] [Abstract][Full Text] [Related]
6. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005).
Deshpande LM; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):367-72. PubMed ID: 17020798
[TBL] [Abstract][Full Text] [Related]
7. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
8. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel.
Colodner R; Samra Z; Keller N; Sprecher H; Block C; Peled N; Lazarovitch T; Bardenstein R; Schwartz-Harari O; Carmeli Y;
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):201-5. PubMed ID: 17258084
[TBL] [Abstract][Full Text] [Related]
9. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
Nijssen S; Florijn A; Bonten MJ; Schmitz FJ; Verhoef J; Fluit AC
Int J Antimicrob Agents; 2004 Dec; 24(6):585-91. PubMed ID: 15555882
[TBL] [Abstract][Full Text] [Related]
10. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
[TBL] [Abstract][Full Text] [Related]
11. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
J Infect Dev Ctries; 2009 May; 3(4):285-94. PubMed ID: 19759492
[TBL] [Abstract][Full Text] [Related]
12. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
J Infect Dev Ctries; 2009 Apr; 3(3):177-86. PubMed ID: 19759472
[TBL] [Abstract][Full Text] [Related]
13. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.
Stürenburg E; Sobottka I; Noor D; Laufs R; Mack D
J Antimicrob Chemother; 2004 Jul; 54(1):134-8. PubMed ID: 15150168
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
[TBL] [Abstract][Full Text] [Related]
16. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.
Wiegand I; Geiss HK; Mack D; Stürenburg E; Seifert H
J Clin Microbiol; 2007 Apr; 45(4):1167-74. PubMed ID: 17287329
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
Korten V; Ulusoy S; Zarakolu P; Mete B;
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
[TBL] [Abstract][Full Text] [Related]
18. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
Livermore DM; Hope R; Mushtaq S; Warner M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: dissemination of CTX-M-2.
Kanamori H; Yano H; Hirakata Y; Endo S; Arai K; Ogawa M; Shimojima M; Aoyagi T; Hatta M; Yamada M; Nishimaki K; Kitagawa M; Kunishima H; Kaku M
J Antimicrob Chemother; 2011 Oct; 66(10):2255-62. PubMed ID: 21733965
[TBL] [Abstract][Full Text] [Related]
20. Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.
Mushtaq S; Hope R; Warner M; Livermore DM
J Antimicrob Chemother; 2007 May; 59(5):1025-30. PubMed ID: 17353220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
